Clinical Trial Update: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life [Phase 3]

View source ↗

Summary

Phase 3 trial update on the immunogenicity and safety of GSK's combined MMR vaccine in children in their second year of life; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Measles
• Mumps
• Rubella

Drugs mentioned

• Combined Measles-Mumps-Rubella Vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Measles, Mumps | Phase 3 | Status: COMPLETED | Results posted: 2018-08-17